Advaxis Inc. shares dropped in the extended session Tuesday after the biotech developer said the Food and Drug Administration issued a clinical hold against one of its drugs affecting four studies. Advaxis shares dropped 28% to $7.40 on heavy volume. The company said the FDA placed the clinical hold on its axalimogene filolisbac treatment studies after one patient died of her end-stage cervical cancer following treament. Advaxis said the FDA has requested information supporting the company’s claim that the medication did not cause the patient’s death.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News